Ticlopidine-induced	ticlopidine-induced	O	O
cholestatic	cholestatic	O	S_disease
hepatitis	hepatitis	O	S_disease
.	.	O	O

OBJECTIVE	objective	O	O
:	:	O	O
To	to	O	O
report	report	O	O
2	2	O	O
cases	cases	O	O
of	of	O	O
ticlopidine-induced	ticlopidine-induced	O	O
cholestatic	cholestatic	O	S_disease
hepatitis	hepatitis	O	S_disease
,	,	O	O
investigate	investigate	O	O
its	its	O	O
mechanism	mechanism	O	O
,	,	O	O
and	and	O	O
compare	compare	O	O
the	the	O	O
observed	observed	O	O
main	main	O	O
characteristics	characteristics	O	O
with	with	O	O
those	those	O	O
of	of	O	O
the	the	O	O
published	published	O	O
cases	cases	O	O
.	.	O	O

CASE	case	O	O
SUMMARIES	summaries	O	O
:	:	O	O
Two	two	O	O
patients	patients	O	O
developed	developed	O	O
prolonged	prolonged	O	O
cholestatic	cholestatic	O	S_disease
hepatitis	hepatitis	O	S_disease
after	after	O	O
receiving	receiving	O	O
ticlopidine	ticlopidine	S_chemicals	O
following	following	O	O
percutaneous	percutaneous	O	O
coronary	coronary	O	O
angioplasty	angioplasty	O	O
,	,	O	O
with	with	O	O
complete	complete	O	O
remission	remission	O	O
during	during	O	O
the	the	O	O
follow-up	follow-up	O	O
period	period	O	O
.	.	O	O

T-cell	t-cell	S_chemicals	S_disease
stimulation	stimulation	O	O
by	by	O	O
therapeutic	therapeutic	O	O
concentration	concentration	O	O
of	of	O	O
ticlopidine	ticlopidine	S_chemicals	O
was	was	O	O
demonstrated	demonstrated	O	O
in	in	O	O
vitro	vitro	O	O
in	in	O	O
the	the	O	O
patients	patients	O	O
,	,	O	O
but	but	O	O
not	not	O	O
in	in	O	O
healthy	healthy	O	O
controls	controls	O	O
.	.	O	O

DISCUSSION	discussion	O	O
:	:	O	O
Cholestatic	cholestatic	O	S_disease
hepatitis	hepatitis	O	S_disease
is	is	O	O
a	a	O	O
rare	rare	O	O
complication	complication	O	O
of	of	O	O
the	the	O	O
antiplatelet	antiplatelet	B_chemicals	O
agent	agent	I_chemicals	O
ticlopidine	ticlopidine	S_chemicals	O
;	;	O	O
several	several	O	O
cases	cases	O	O
have	have	O	O
been	been	O	O
reported	reported	O	O
but	but	O	O
few	few	O	O
in	in	O	O
the	the	O	O
English	english	O	O
literature	literature	O	O
.	.	O	O

Our	our	O	O
patients	patients	O	O
developed	developed	O	O
jaundice	jaundice	O	S_disease
following	following	O	O
treatment	treatment	O	O
with	with	O	O
ticlopidine	ticlopidine	S_chemicals	O
and	and	O	O
showed	showed	O	O
the	the	O	O
clinical	clinical	O	O
and	and	O	O
laboratory	laboratory	O	O
characteristics	characteristics	O	O
of	of	O	O
cholestatic	cholestatic	O	S_disease
hepatitis	hepatitis	O	S_disease
,	,	O	O
which	which	O	O
resolved	resolved	O	O
after	after	O	O
discontinuation	discontinuation	O	O
of	of	O	O
the	the	O	O
drug	drug	S_chemicals	O
.	.	O	O

Hepatitis	hepatitis	O	S_disease
may	may	O	O
develop	develop	O	O
weeks	weeks	O	O
after	after	O	O
discontinuation	discontinuation	O	O
of	of	O	O
the	the	O	O
drug	drug	S_chemicals	O
and	and	O	O
may	may	O	O
run	run	O	O
a	a	O	O
prolonged	prolonged	O	O
course	course	O	O
,	,	O	O
but	but	O	O
complete	complete	O	O
remission	remission	O	O
was	was	O	O
observed	observed	O	O
in	in	O	O
all	all	O	O
reported	reported	O	O
cases	cases	O	O
.	.	O	O

An	an	O	O
objective	objective	O	O
causality	causality	O	O
assessment	assessment	O	O
revealed	revealed	O	O
that	that	O	O
the	the	O	O
adverse	adverse	O	B_disease
drug	drug	S_chemicals	B_disease
event	event	O	I_disease
was	was	O	O
probably	probably	O	O
related	related	O	O
to	to	O	O
the	the	O	O
use	use	O	O
of	of	O	O
ticlopidine	ticlopidine	S_chemicals	O
.	.	O	O

The	the	O	O
mechanisms	mechanisms	O	O
of	of	O	O
this	this	O	O
ticlopidine-induced	ticlopidine-induced	O	O
cholestasis	cholestasis	O	S_disease
are	are	O	O
unclear	unclear	O	O
.	.	O	O

Immune	immune	O	O
mechanisms	mechanisms	O	O
may	may	O	O
be	be	O	O
involved	involved	O	O
in	in	O	O
the	the	O	O
drug	drug	S_chemicals	O
's	's	O	O
hepatotoxicity	hepatotoxicity	O	O
,	,	O	O
as	as	O	O
suggested	suggested	O	O
by	by	O	O
the	the	O	O
T-cell	t-cell	S_chemicals	S_disease
stimulation	stimulation	O	O
study	study	O	O
reported	reported	O	O
here	here	O	O
.	.	O	O

CONCLUSIONS	conclusions	O	O
:	:	O	O
Cholestatic	cholestatic	O	S_disease
hepatitis	hepatitis	O	S_disease
is	is	O	O
a	a	O	O
rare	rare	O	O
adverse	adverse	O	O
effect	effect	O	O
of	of	O	O
ticlopidine	ticlopidine	S_chemicals	O
that	that	O	O
may	may	O	O
be	be	O	O
immune	immune	O	O
mediated	mediated	O	O
.	.	O	O

Patients	patients	O	O
receiving	receiving	O	O
the	the	O	O
drug	drug	S_chemicals	O
should	should	O	O
be	be	O	O
monitored	monitored	O	O
with	with	O	O
liver	liver	O	O
function	function	O	O
tests	tests	O	O
along	along	O	O
with	with	O	O
complete	complete	O	O
blood	blood	O	O
cell	cell	O	O
counts	counts	O	O
.	.	O	O

This	this	O	O
complication	complication	O	O
will	will	O	O
be	be	O	O
observed	observed	O	O
even	even	O	O
less	less	O	O
often	often	O	O
in	in	O	O
the	the	O	O
future	future	O	O
as	as	O	O
ticlopidine	ticlopidine	S_chemicals	O
is	is	O	O
being	being	O	O
replaced	replaced	O	O
by	by	O	O
the	the	O	O
newer	newer	O	O
antiplatelet	antiplatelet	B_chemicals	O
agent	agent	I_chemicals	O
clopidogrel	clopidogrel	O	O
.	.	O	O

